Kisspeptin-10 IHH Case Series: PMID 30430143

PMID 30430143 reports a seven-person academic case series asking whether sex-steroid treatment could restore an acute luteinizing-hormone (LH) response to kisspeptin-10 in people with idiopathic hypogonadotropic hypogonadism, or IHH. The authors reported no kisspeptin response in the seven participants studied on sex-steroid therapy or the five studied off therapy. All seven responded to a separate gonadotropin-releasing-hormone (GnRH) probe, in an experiment that included prior pituitary priming for six participants. This is a narrow physiologic observation, not a test of fertility, clinical benefit, long-term safety, or equivalence to another material.[1][2]

Study at a glance

The protocol attributes above describe the experiment. They are not preparation, administration, or treatment instructions.

Why this was a physiologic probe, not an efficacy trial

IHH can arise from defects at different points in the reproductive neuroendocrine pathway. The investigators selected participants who appeared more likely than a classic complete-IHH population to retain some hypothalamic-pituitary-gonadal activity. Six of seven had evidence such as partial spontaneous development, detectable LH secretion, or prior axis activity. People with genetic findings expected to remove an essential component of kisspeptin or GnRH signaling were excluded.[1]

The experiment used frequent LH sampling to look for an acute kisspeptin response. A separate GnRH probe assessed whether pituitary gonadotropes could release LH when stimulated downstream. Six participants first underwent pituitary priming with GnRH, stopped before the experimental visit; the remaining participant had prior evidence of an endogenously primed pituitary. Preserved GnRH responsiveness must therefore be interpreted under those experimental conditions, not as an untreated baseline property of every participant.[1]

Genetic screening informed selection, but did not prove that every relevant receptor, neuron, or signaling pathway was functional. The experiment can distinguish response patterns, not establish that a repeated intervention improves symptoms, completes puberty, restores gamete production, or changes a patient-important outcome. The guide to reading a research study explains this design-to-claim boundary.

Participant flow and paired data

Seven participants entered the series: six men and one woman. All were studied while receiving their prescribed sex-steroid therapy. Five also completed an off-sex-steroid visit; two participants did not complete that visit. Five of seven had previously undergone detailed overnight neuroendocrine phenotyping, and the case series drew participants from a pre-existing research cohort.[1]

That structure matters. The headline “seven participants” is correct for the on-treatment observation, but only five supplied paired on-versus-off data. The sample was also intentionally enriched for people thought capable of responding, rather than enrolled as a consecutive or representative IHH cohort. There was no randomized allocation, placebo comparison, or concurrent healthy-control group.[1]

Main LH-response result

The authors reported no kisspeptin response in either observed condition. Table 3 gives maximum LH increases within 30 minutes of 0.0–0.4 mIU/mL off sex steroids and 0.0–0.2 mIU/mL on sex steroids.[1]

The methods describe a validated pulse-identification approach and calculate pulse amplitude from the peak relative to LH at the time of the kisspeptin probe; a decrease was assigned zero. Thus, a zero in the table is not proof of an exactly flat hormone trace, and small positive changes were not classified by the authors as kisspeptin responses. This summary does not invent a numerical responder cutoff or claim independent verification of a prospectively locked threshold.[1]

All seven responded to the separate GnRH probe. For the available male observations, reported GnRH-stimulated LH amplitudes ranged from 2.2 to 23 mIU/mL off testosterone and from 2 to 13 mIU/mL on testosterone; the off-treatment range does not represent all six men. The female participant's amplitudes were 18.1 off and 1.8 mIU/mL on oral-contraceptive therapy. The authors attributed the smaller on-treatment response to estrogen feedback; this was not an independently randomized test of that explanation.[1]

The contrast between absent kisspeptin response and preserved GnRH response supports the authors' interpretation that pituitary failure alone did not explain the null kisspeptin finding. It does not identify a single molecular defect. The paper discusses several possible downstream mechanisms, including receptor expression, trafficking, signaling, GnRH-neuron function, and other neuronal cofactors; these are hypotheses, not measured causal findings.[1]

Statistical interpretation

This was a descriptive case series, not a powered randomized trial. Although the methods state a general p<0.05 significance convention, the kisspeptin comparison is reported through participant-level amplitudes and ranges, without a comparative p-value, treatment-effect confidence interval, or population response-rate interval. No formal estimand, multiplicity strategy, or standalone analysis plan for this seven-person subset was independently obtained. Paired on/off samples were assayed in the same laboratory, while different participants' samples could be processed in different laboratories.[1]

“No responders” describes the authors' assessment within this experiment; it does not prove that every person with IHH is incapable of responding under every condition. The acute probe, priming, assay timing, sex-steroid context, selection criteria, and incomplete paired data constrain the inference. See interpreting negative and null study results.

Outcomes the study did not measure

The measured endpoint was acute LH change. The report did not test sperm production, ovulation, pregnancy, live birth, sustained testosterone or estradiol production, completion of puberty, symptoms, quality of life, or long-term endocrine outcomes. It also did not compare alternative kisspeptin forms, long-term schedules, or clinical management strategies.[1]

The separate GnRH response demonstrated short-term pituitary capacity under the study conditions. It should not be described as restored fertility or normalization of the broader reproductive axis. The laboratory-endpoint and clinical-outcome guide explains why a hormone measurement cannot substitute automatically for a patient-important result.

Adverse events and safety reporting

The article does not provide an adverse-event table or a systematic safety-outcome section. Neither cited ClinicalTrials.gov parent record posts study-specific summary results for this seven-person series. Consequently, the paper cannot support a quantitative adverse-event rate or a conclusion that the protocol was generally safe.[1][3][4]

Missing safety reporting is not a zero adverse-event count. The small sample, acute exposure, and lack of a dedicated safety dataset make the record unsuitable for estimating uncommon, delayed, reproductive, or long-term harms. The adverse-event reporting guide distinguishes missing data from a measured absence of events.

Registry scope and results-posting limits

The fresh official records distinguish two broad parent studies:[3][4]

Neither record posts summary results or a protocol/SAP document in its current public document section. Their totals must not replace the paper's seven-person denominator. The paper explicitly cites both identifiers, establishing the reported lineage, but the registries do not independently reproduce this subset's paired-data pattern or result table. This review did not obtain a standalone protocol/SAP or individual-level dataset for reanalysis. For ongoing checks, use the trial and FDA status guide.

Funding and conflicts

The published acknowledgments list NIH/NICHD awards and intramural support, Harvard Catalyst, a Doris Duke Clinical Scientist Development Award, and institutional fellowship support. The authors reported nothing to disclose. Massachusetts General Hospital is the lead sponsor of both parent records. The paper says NeoMPS synthesized the study peptides using good manufacturing practices and supplied kisspeptin under a NICHD contract. These are reported study-source facts, not an independent audit of manufacturing or of a present-day supplier.[1][3][4]

Public funding and no declared conflicts do not remove selection, small-sample, incomplete-visit, or control-group limitations. No detailed allocation of every funder's role in design, analysis, and publication was established in this review.

How to interpret significance, effect size, and uncertainty

• Observed result: zero of seven participants responded to kisspeptin while on sex-steroid therapy; zero of five responded during the off-treatment observation.
• Effect size: the study did not estimate a randomized between-group treatment effect.
• Uncertainty: no confidence interval was reported for a population response rate, and the selected sample was extremely small.
• Clinical importance: an acute LH probe is mechanistic evidence, not a fertility or clinical-benefit outcome.

Important limitations

• The case series included seven selected participants, only five with paired on/off observations.
• There was no randomized placebo group or concurrent healthy-control group.
• Selection favored people thought more likely to retain relevant neuroendocrine capacity, limiting generalizability.
• The endpoint was an acute laboratory hormone response, not a patient-important reproductive outcome.
• No systematic adverse-event dataset was reported.
• The cited registry records are broad parent protocols and do not post results for this exact seven-person analysis.
• The study cannot determine which proposed downstream mechanism explains the observed response pattern.

What this study does not prove

PMID 30430143 does not prove that kisspeptin-10 is effective or ineffective as a treatment for every person with IHH. It does not establish effects on sperm, ovulation, pregnancy, live birth, puberty, symptoms, quality of life, or long-term hormone production. It does not establish regulatory approval or a general safety profile.

The paper studied kisspeptin 112–121, the ten-amino-acid form, not kisspeptin-54. It does not compare those forms or authenticate another source's material. A name match does not establish the same sequence, formulation, quality, or exposure. Related identity boundaries are discussed in the growth-hormone and endocrine research library and the peptide structural-identity guide.

Dated FDA context is separate from the experiment

At the source check, FDA's May 14, 2026 category document listed kisspeptin-10 in Category 2 under its section 503A interim compounding policy. FDA's current risk summary identifies potential immune reactions, peptide-impurity and active-ingredient-characterization complexities, and insufficient safety information for proposed routes. Its kisspeptin-10 row dates category entry to September 29, 2023.[5][6]

This is a U.S. compounding-policy status and safety warning, not evidence of FDA approval, a worldwide legal determination, or proof that every exposed individual will be harmed. The 2018 case series does not establish an approved finished product. Research participation and a matching ingredient name do not create approval or lot equivalence; see approved drugs versus research materials.

Frequently asked questions

How many people were included?

Seven people with IHH participated: six men and one woman. All seven had an on-sex-steroid observation; five also completed an off-sex-steroid visit.

Was this a randomized clinical trial?

No. It was a selected academic case series with within-person observations where paired data were available.

What was the main outcome?

The paper reported acute LH responses, including maximum increases within 30 minutes after the kisspeptin-10 probe. Decreases were assigned zero in the amplitude summary.

Did any participant respond to kisspeptin-10?

The authors reported no kisspeptin responders among seven on-treatment or five off-treatment observations. This is not an independently verified universal response threshold or an equivalence finding.

Why was GnRH also tested?

It tested downstream pituitary responsiveness. All seven responded, but six had undergone prior pituitary priming and one had evidence of endogenous priming. That context is part of the finding.

Did the study measure fertility or pregnancy?

No. It did not measure sperm production, ovulation, pregnancy, live birth, or sustained restoration of reproductive function.

Does the paper establish safety or catalog equivalence?

No. It lacks a systematic adverse-event dataset and does not validate any separately sourced material.

Primary and official sources

1. Primary full paper: kisspeptin responsiveness in IHH, PMCID PMC6223246
2. PubMed: PMID 30430143
3. ClinicalTrials.gov parent protocol: NCT00914823
4. ClinicalTrials.gov observational parent protocol: NCT00494169
5. FDA section 503A nominated-substance categories, updated May 14, 2026
6. FDA compounding substances that may present significant safety risks

Review and corrections

Sources checked September 2, 2026 (America/Edmonton) / September 3, 2026 (UTC). Serum Research is responsible for this editorial summary; no independent clinical, statistical, scientific, analytical, or regulatory review of this page is claimed. The published article, current parent records, and cited FDA materials were reviewed; a separate subset-specific protocol/SAP and systematic safety dataset were not obtained. This is not medical advice or a conclusion about any material's quality or equivalence.

See how we review evidence, browse the study-record index or research library, and send a correction with the relevant source and passage.